Multiple Sclerosis News and Research

Latest Multiple Sclerosis News and Research

AANF changes name to American Brain Foundation

The American Academy of Neurology Foundation is now the American Brain Foundation. The name change is part of an overall re-branding campaign as the organization repositions itself to become the world's leader in raising money for research to cure brain diseases, such as Alzheimer's disease, stroke, Parkinson's disease, autism, and epilepsy.

25 Apr 2012

Biogen Idec announces positive data from oral BG-12 second Phase 3 trial on RRMS

Today Biogen Idec announced that detailed positive data from CONFIRM, the second Phase 3 clinical trial of oral BG-12 (dimethyl fumarate) in people with relapsing-remitting multiple sclerosis (RRMS), will be presented in three platform presentations at the 64th Annual Meeting of the American Academy of Neurology (AAN) in New Orleans.

25 Apr 2012

Preventive treatments can reduce migraine attacks

Research shows that many treatments can help prevent migraine in certain people, yet few people with migraine who are candidates for these preventive treatments actually use them, according to new guidelines issued by the American Academy of Neurology.

24 Apr 2012

Medgenics seeks FDA Orphan Drug Designation for INFRADURE to treat hepatitis D

Medgenics, Inc., the developer of a novel technology for the sustained production and delivery of therapeutic proteins in patients using their own tissue, today announced that it has filed for Orphan Drug Designation with the U.S. Food and Drug Administration (FDA) for INFRADURE for the treatment of hepatitis D.

23 Apr 2012

Nano-devices cross blood-brain barrier to deliver drug to treat cerebral palsy

A team of scientists from Johns Hopkins and elsewhere have developed nano-devices that successfully cross the brain-blood barrier and deliver a drug that tames brain-damaging inflammation in rabbits with cerebral palsy.

23 Apr 2012

LCIG improves quality of life, reduces symptoms of Parkinson's

A recent clinical trial conducted at Evergreen Healthcare shows that a new form of a common drug used to treat Parkinson's Disease greatly improves the quality of life for patients and reduces the affects of symptoms such as tremors, slowness, stiffness and difficulty walking.

21 Apr 2012

Kessler Foundation scientist to develop predictive model of unemployment in MS

Lauren Strober, PhD, has been awarded a five-year federal grant for $554,000 to study factors relating to unemployment in people with multiple sclerosis (MS). Dr. Strober is a research scientist at Kessler Foundation, a major center for cognitive research and training in multiple sclerosis and a leader in the field of disability employment.

20 Apr 2012

Interferon beta-1a shows promise against MS

People who received injections of the multiple sclerosis (MS) drug interferon beta-1a soon after their first signs of possible MS were less likely to progress to clinically definite MS than people who switched to interferon beta-1a from placebo, according to new phase three results of the three-year REFLEXION clinical trial that will be presented as part of the Emerging Science program at the American Academy of Neurology's 64th Annual Meeting in New Orleans, April 21 to April 28, 2012.

20 Apr 2012

Clinical study to evaluate high-dose vitamin D supplements for MS

Doctors at several centers across the U.S. are recruiting people who have multiple sclerosis (MS) to determine the effectiveness of high-dose vitamin D supplements for reducing MS disease activity.

20 Apr 2012

SBU to advance research and clinical care at National Pediatric MS Center

Stony Brook University has received a $2.5 million gift from Robert and Lisa Lourie to advance research and clinical care at the National Pediatric Multiple Sclerosis (MS) Center at Stony Brook Long Island Children's Hospital and to establish a new state-of-the-art imaging center at Stony Brook Medicine.

19 Apr 2012

Abbott reports positive results from LCIG Phase 3 trial for advanced Parkinson's disease

Abbott announced today the results from a Phase 3 trial evaluating the company's investigational compound for advanced Parkinson's disease, levodopa-carbidopa intestinal gel (LCIG).

18 Apr 2012

Levodopa-carbidopa intestinal gel better than standard oral form to treat advanced Parkinson's disease

A levodopa-carbidopa intestinal gel (LCIG) works better than standard oral levodopa-carbidopa in reducing "off" time in patients with advanced Parkinson's disease.

18 Apr 2012

Medgenics seeks IND approval to initiate EPODURE Biopump Phase IIb anemia study in ESRD patients

Medgenics, Inc., the developer of a novel technology for the sustained production and delivery of therapeutic proteins in patients using their own tissue, today announced that it has filed an Investigational New Drug application with the U.S. Food and Drug Administration to initiate a Phase IIb multi-center, 100-patient clinical trial.

18 Apr 2012

ONO-4641 reduces number of lesions in people with MS

An investigational oral drug called ONO-4641 reduced the number of lesions in people with multiple sclerosis (MS), according to the results of a phase two clinical trial to be presented as Emerging Science at the American Academy of Neurology's 64th Annual Meeting in New Orleans April 21 to April 28, 2012.

17 Apr 2012

Synthon receives tentative approval for tadalafil tablets

Synthon has announced that its subsidiary Synthon Pharmaceuticals, Inc. has received tentative approval from the U.S. Food and Drug Administration (FDA) for its abbreviated new drug application for tadalafil tablets, 20 mg on April 13, 2012. Synthon's product is a generic and bioequivalent version of Eli Lilly & Co and United Therapeutics’ Adcirca® tablets, which are indicated for the treatment of pulmonary arterial hypertension to improve exercise ability.

16 Apr 2012

TGF-β molecule ramps up the immune system in some cases and suppress it in others

Loyola researchers are reporting surprising findings about a molecule that helps ramp up the immune system in some cases and suppress it in others.

16 Apr 2012

New drug to detect beta-amyloid plaques may help diagnose AD earlier

Use of a new drug to detect the beta-amyloid plaques in the brain that are hallmark signs of Alzheimer's disease may help doctors diagnose the disease earlier, according to research that will be presented as part of the Emerging Science program (formerly known as Late-Breaking Science) at the American Academy of Neurology's 64th Annual Meeting in New Orleans April 21 to April 28, 2012.

16 Apr 2012

Neurological symptoms due to a bump on the head should not be ignored

When Dr. Irene Gatti de Leon slipped on the ice and bumped her head, she wasn't too concerned. But two months later, she began to experience weakness in her right leg and right arm while she and her husband were visiting their daughter in suburban Chicago.

16 Apr 2012

New genes may explain individual differences in brain size and intelligence

In the world's largest brain study to date, a team of more than 200 scientists from 100 institutions worldwide collaborated to map the human genes that boost or sabotage the brain's resistance to a variety of mental illnesses and Alzheimer's disease.

16 Apr 2012

Roundup: Texas considers relaxing rules for stem cell treatments; States weigh bills to protect consumers against high drug costs

A Texas agency will vote Friday on whether to enact new rules that would make it easier for doctors to offer experimental treatments using adult stem cells without federal approval. The Texas Medical Board, which licenses and disciplines doctors in the state, recently drafted stem-cell rules at the behest of Dr. Stanley Jones of Houston, who in July injected Gov. Rick Perry with the governor's own stem cells to try to aid his recovery from a back injury.

16 Apr 2012